References
- Gertz MA, Landau H, Comenzo RL, Seldin D, Weiss B, Zonder J, Merlini G, et al. First-in-human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol 2016;34:1097–103.
- Langer AL, Miao S, Mapara M, Radhakrishnan J, Maurer MS, Raza S, Mearset JG, et al. Results of phase i study of chimeric fibril-reactive monoclonal antibody 11-1f4 in patients with AL amyloidosis. Blood 2015;126:188.